pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 12·1 min read
save

Commure's AI-driven referral program draws complaints of financial losses from health-care customers

Aug 12, 2026·read at STAT ↗Negative

Commure, a Silicon Valley startup valued at $7 billion, builds AI tools aimed at automating health‑care administrative work such as scheduling, billing and prior‑authorization.

According to internal communications obtained by STAT, the company runs a referral program that pays thousands of dollars to customers and other parties who bring in new business. The firm says this practice is common in the industry.

However, several clinic customers have told investigators that the AI tools failed to deliver expected savings and instead caused steep financial losses and other problems, raising concerns about the real‑world impact of the technology.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care”

read at STAT ↗
855 words · retrieved Aug 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
MOUNTAINNEUROCRINENEUROCRINE BIOSCIENCES INCTENET HEALTHCARE CORPUltragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
CardiologyRare DiseaseVaccines

related stories

  • Aug 12STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts saySTAT
  • Aug 13STAT+: Eli Lilly targets booming black market for retatrutideSTAT
  • Aug 13STAT+: Neurocrine Biosciences and the delicate balance of benefit and riskSTAT
  • Aug 12Deaths reported after treatment with Neurocrine’s approved Prader-Willi drugBioSpace
  • Aug 12STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and moreSTAT